Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 18 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 18 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 27 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 27 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 36 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 36 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 54 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 54 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - English - Ministry of Health

j-c health care ltd - ibrutinib - capsules - ibrutinib 140 mg - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.